CORDIS
Resultados de investigaciones de la UE

CORDIS

Español ES

Nanomedicine upscaling for early clinical phases of multimodal cancer therapy

Objetivo

During the last four years the Multifun Consortium (FP7 project Nº. 262943) has developed and validated distinct nanoformulations as therapeutic approach against pancreatic and breast cancer. These nanoformulations are based on magnetic iron oxide nanoparticles (MNP) multifuntionalised with a target peptide and an anticancer chemical drug, allowing for a synergistic therapeutic effect produced by the combination of intracellular drug delivery and magnetic hyperthermia. In particular, some of the designed formulations (patent filed PCT/EP2015/056631) have proven their efficacy, safety and non-toxicicty, in in vitro and in vivo studies, against the mentioned cancers, thus making them promising candidates to produce a novel nanomedicine therapy for cancer.

NoCanTher aims at translating one of these nanoformulations to early clinical development for pancreatic cancer. To successfully reach this objective, we will concentrate our efforts in two main group of activities:
• Nanomedicine up-scaling under GMP conditions: NoCanTher will scale up the manufacturing of the proposed nanoformulation from milligram-scale laboratory synthesis up to multigram-scale production to generate sufficient material for clinical and regulatory assays. To this aim, a GMP production line will be optimised and the relevant quality control will be conducted at the different stages of the up-scaling process.
• Clinical trial: NoCanTher will include late preclinical parameter testing to raise a clinical treatment protocol, regulatory assays, as well as the design of the clinical trial and the preparation of the Investigational Medicinal Product Dossier (IMPD).

This strategy will allow us to apply for Clinical Trial Authorisation (CTA) then, we will carry out a Phase I clinical trial.
NoCanTher involves the participation of institutions from three different sectors (academia, industry, clinical) and from five different countries (Ireland, France, Germany, Spain and the UK).

Coordinador

FUNDACION IMDEA NANOCIENCIA

Dirección

Ciudad Universitaria De Cantoblanco - Calle Faraday 9
28049 Madrid

España

Tipo de actividad

Research Organisations

Aportación de la UE

€ 665 000

Participantes (11)

Ordenar alfabéticamente

Ordenar por aportación de la UE

Ampliar todo

BIOKERALTY RESEARCH INSTITUTE AIE

España

Aportación de la UE

€ 1 302 240

IMMUPHARMA PLC

Reino Unido

Aportación de la UE

€ 427 820

CHEMICELL GMBH

Alemania

Aportación de la UE

€ 400 000

FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III

España

Aportación de la UE

€ 88 538,36

Universitätsklinikum Jena

Alemania

Aportación de la UE

€ 765 125

RESONANT CIRCUITS LIMITED

Reino Unido

Aportación de la UE

€ 700 000

FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA

España

Aportación de la UE

€ 549 441,25

THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN

Irlanda

Aportación de la UE

€ 691 847,50

UNIVERSITE PARIS DIDEROT - PARIS 7

Francia

Aportación de la UE

€ 611 000

FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON

España

Aportación de la UE

€ 352 287,50

HOSPITAL UNIVERSITARIO DE FUENLABRADA

España

Aportación de la UE

€ 560 479,14

Información del proyecto

Identificador del acuerdo de subvención: 685795

Estado

Proyecto en curso

  • Fecha de inicio

    1 Abril 2016

  • Fecha de finalización

    31 Marzo 2021

Financiado con arreglo a:

H2020-EU.2.1.2.

  • Presupuesto general:

    € 7 113 778,75

  • Aportación de la UE

    € 7 113 778,75

Coordinado por:

FUNDACION IMDEA NANOCIENCIA

España